Bisoprolol Fumarate And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 50090-5905

6 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bisoprolol Fumarate And Hydrochlorothiazide (NDC 50090-5905). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Biso Api Structure (Api Pic New1)

Biso Api Structure (Api Pic New1)
Chemical structure of Bisoprolol Fumarate and Hydrochlorothiazide active ingredients, showing molecular configurations and bonding patterns for these compounds.*
FDA Label Image

Hctz Api Structure (Api Pic New2)

Hctz Api Structure (Api Pic New2)
Chemical structure of the active ingredient bisoprolol fumarate and hydrochlorothiazide showing a benzene ring with chlorine, sulfonamide, and amino substituents.*
FDA Label Image

Label Image (Lbl500905905)

Label Image (Lbl500905905)
Label for Bisoprolol Fumarate and Hydrochlorothiazide 10 mg/6.25 mg film-coated tablets from A-S Medication Solutions. The label indicates 30 tablets in the package, with storage instructions to keep at 68 to 77 degrees Fahrenheit. It includes the product NDC 50090-5905-0 and dispensing instructions as a prescription medication.*
FDA Label Image

Table 1 (Table 1 New)

Table 1 (Table 1 New)
A data table showing mean decreases in sitting systolic/diastolic blood pressure and heart rate after 3-4 weeks from two studies comparing placebo and various doses of Bisoprolol Fumarate and Hydrochlorothiazide combinations. The table includes total changes and drug effects with values in mm Hg for blood pressure and bpm for heart rate.*
FDA Label Image

Table-3 (Table 3 New)

Table-3 (Table 3 New)
A data table presenting the percentage of patients experiencing various adverse experiences categorized by body system for Bisoprolol Fumarate and Hydrochlorothiazide 10 mg/6.25 mg compared to placebo. The table separates all adverse experiences and drug-related adverse experiences, listing conditions such as cardiovascular, respiratory, central nervous system, musculoskeletal, psychiatric, and gastrointestinal events with specific percentages for each treatment group.*
FDA Label Image

Table-2 (Table New 2)

Table-2 (Table New 2)
A data table titled 'Serum Potassium Data from U.S. Placebo Controlled Studies' comparing potassium-related effects across placebo and various doses of Bisoprolol Fumarate and Hydrochlorothiazide, including mean change in potassium levels and incidence of hypokalemia (%) for groups with sample sizes listed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.